Nikhil S Sakle
Nikhil S Sakle is an expert in Pharmacy at M.S. Ramaiah Medical College (India). Nikhil S Sakle has authored 25 publications, the most recent in 2025. SLR score: 63 (community average: 125). How the SLR is computed.
LeadR Profile
Pharmacy
Subspecialties: Oncology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2009 - 2023
Number : 25
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Exploring the Potential of Dolutegravir in Alzheimer's Disease Treatment: Insights from Network Pharmacology and In Silico Docking Studies. PMID 40231534 — genes, alzheimer disease, pharmaceutical preparations, chemistry, pharmaceutical, pharmacology, therapeutics, amyloid, dolutegravir | Cent Nerv Syst Agents Med Chem | 2025 | 0 |
| Investigating Vitamin D's anticancer mechanisms in MCF-7 cells: a network pharmacology and omics technology approach. PMID 40146431 — cells, mcf-7 cells, breast neoplasms, vitamins, molecular biology, neoplasms, pharmacology, breast, therapeutics, apoptosis, evolution, molecular | Mol Divers | 2025 | 0 |
| KRAS inhibitors in drug resistance and potential for combination therapy. PMID 39506389 — cells, pharmaceutical preparations, neoplasms, therapeutics, drug resistance | Tumori | 2024 | 0 |
| Exploring the therapeutic potential of SGLT2 inhibitors in cancer treatment: integrating in silico and in vitro investigations. PMID 38416196 — pharmacology, cells, therapeutics, neoplasms, genes, cell line, symporters, sodium-glucose transporter 2 inhibitors | Naunyn Schmiedebergs Arch Pharmacol | 2024 | 7 |
| Integrative network pharmacology, molecular docking, and dynamic simulation analysis of a polyherbal formulation for potential therapeutic impact on prostate cancer. PMID 39114070 — neoplasms, prostate, pharmacology, prostatic neoplasms, therapeutics | Heliyon | 2024 | 2 |
LeadR Networks
Main global connection map